N-(cyanomethyl)-2-methyl-4-(2-(4-morpholinophenylamino)pyrimidin-4-yl)benzamide | 1056634-91-3

• 分子结构分类: 有机化合物 - 有机杂环化合物
• 英文名称: N-(cyanomethyl)-2-methyl-4-(2-(4-morpholinophenylamino)pyrimidin-4-yl)benzamide
• 英文别名: N-(cyanomethyl)-2-methyl-4-[2-(4-morpholin-4-ylanilino)pyrimidin-4-yl]benzamide
• CAS: 1056634-91-3
• 化学式: C₂₄H₂₄N₆O₂
• 分子量: 428.494
• InChiKey: HFNYDUGXJCRIRE-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.9
• 重原子数：
  32
• 可旋转键数：
  6
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  103
• 氢给体数：
  2
• 氢受体数：
  7

文献信息

• PHENYL AMINO PYRIMIDINE COMPOUNDS AND USES THEREOF
  申请人：Burns Christopher John

  公开号：US20100197671A1

  公开（公告）日：2010-08-05

  The present invention relates to phenyl amino pyrimidine compounds which are inhibitors of protein kinases including JAK kinases. In particular the compounds are selective for JAK2 kinases. The kinase inhibitors can be used in the treatment of kinase associated diseases such as immunological and inflammatory diseases including organ transplants; hyperproliferative diseases including cancer and myeloproliferative diseases; viral diseases; metabolic diseases; and vascular diseases.

  本发明涉及苯基氨基嘧啶化合物，它们是蛋白激酶抑制剂，包括JAK激酶。特别是，这些化合物对JAK2激酶具有选择性。这些激酶抑制剂可用于治疗与激酶相关的疾病，如免疫和炎症性疾病，包括器官移植；增生性疾病，包括癌症和骨髓增生性疾病；病毒性疾病；代谢性疾病；以及血管性疾病。
• MULTIPLE MYELOMA TREATMENT
  申请人：Burns Christopher John

  公开号：US20140171433A1

  公开（公告）日：2014-06-19

  A method of treating a subject presenting with multiple myeloma at a stage characterized by an increase in the prevalence of MM cells that (1) are IL-6 non-responsive and/or (2) have a CD45− phenotype, comprising administering to the subject an amount of a compound of formula Ib.

  一种治疗多发性骨髓瘤患者的方法，该患者处于以增加MM细胞的流行为特征的阶段，这些细胞(1)不响应IL-6和/或(2)具有CD45−表型，包括向患者施用Ib式化合物的数量。
• TREATMENT OF JAK2-MEDIATED CONDITIONS
  申请人：Smith Gregg D.

  公开号：US20140073643A1

  公开（公告）日：2014-03-13

  Described herein is a method for treating a subject experiencing anemia, comprising administering to the subject an amount of N-(cyanomethyl)-4-[2-[[4-(4-morpholinyl)phenyl]amino]-4-pyrimidinyl]-benzamide [CYT387 ] or a related compound effective to maintain or elevate the hemoglobin level. The anemic subjects including those afflicted with a myeloproliferative disorder, such as primary myelofibrosis.

  本文描述了一种治疗贫血患者的方法，包括向患者施用足够的N-(氰甲基)-4-[2-[[4-(4-吗啡基)苯基]氨基]-4-嘧啶基]-苯甲酰胺[CYT387]或相关化合物，以维持或提高血红蛋白水平。贫血患者包括那些患有骨髓增生性疾病，如原发性骨髓纤维化的患者。
• Phenyl Amino Pyrimidine Compounds and Uses Thereof
  申请人：Sierra Oncology, Inc.

  公开号：US20220388967A1

  公开（公告）日：2022-12-08

  The present invention relates to phenyl amino pyrimidine compounds which are inhibitors of protein kinases including JAK kinases. In particular the compounds are selective for JAK2 kinases. The kinase inhibitors can be used in the treatment of kinase associated diseases such as immunological and inflammatory diseases including organ transplants; hyperproliferative diseases including cancer and myeloproliferative diseases; viral diseases; metabolic diseases; and vascular diseases.
• US8486941B2
  申请人：——

  公开号：US8486941B2

  公开（公告）日：2013-07-16